WeVote
Log In

Bill

Bill

HB 1571

Pharmacists.

2025 Regular Session Introduced by Lori Goss-Reaves

Indiana bill modifying pharmacist regulations and scope of practice, currently in early committee review stage with unclear specific provisions.

First reading: referred to Committee on Public Health
#agencies;departmentofhealth(idoh) #civillawandprocedure;immunityandexemptionfromliability #healthcarefacilities;pharmacies #healthcareprofessionals;pharmacists #health;abortion #health;billingandcosts #health;prescriptiondrugsandmedications
0
WeVote Research Nonpartisan
Bill Summary · HB 1571

Legislative bill overview

HB 1571 is an Indiana bill authored by Representative Lori Goss-Reaves that addresses pharmacist-related regulations or scope of practice. The bill was introduced on January 21, 2025, and referred to the Committee on Public Health for initial review. Without access to the full bill text, the specific provisions remain unclear, but the referral to Public Health suggests it may expand or modify pharmacist responsibilities, licensing requirements, or patient care authority.

Why is this important

Pharmacist scope-of-practice legislation directly affects how medication services are delivered to patients and can influence healthcare costs and accessibility. Changes to pharmacist authority can impact patients' access to certain medications or services, potentially reducing wait times for routine prescriptions or vaccines, while also affecting competition within healthcare professions and pharmacy business models.

Potential points of contention

  • Scope expansion vs. physician concerns: Proposals to allow pharmacists independent prescribing authority or expanded clinical roles may face opposition from physician organizations who view it as encroaching on their domain
  • Insurance and reimbursement: Changes to what services pharmacists can provide may require corresponding changes to insurance coverage and payment structures, creating costs for payers
  • Consistency with federal regulations: State-level pharmacist authority changes must align with federal pharmacy regulations and DEA controlled substance rules, which can create implementation challenges

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.